Should You Screen for Prostate Cancer? Why the UK Said No, and Why We're Not Convinced

Should you get screened for prostate cancer? For most men in the UK, the official answer in 2026 is no, and that one fact sits on top of one of the most important and most contested debates in men's health. In March 2026, the UK's screening advisers decided against offering prostate cancer screening to the general population. They recommended it for only a very small group of high-risk men.

That decision is defensible on its own terms, and it is also incomplete. To understand why, you need to look at three things: the study the case against screening was built on, what actually happened in the United States when it pulled back on screening, and how much the screening tools themselves have changed. By the end, the question turns out not to be whether screening works. It is whether you can get access to a modern screening pathway, because that access changes the answer for you.

What a PSA test actually measures

PSA stands for prostate-specific antigen, a protein your prostate makes to keep semen in a liquid state. A small amount of it leaks into your blood, and that is what a PSA test measures. As the prostate grows, which happens to nearly all men with age, the amount of PSA in the blood tends to rise too. The original idea was simple: a high PSA could mean a larger or troubled prostate, which could mean cancer.

The trouble is that a single PSA reading is noisy. Your value can swing by around 15% from one day to the next for no important reason. Recent sex can push it up by as much as 40%. And the spread between men is huge. A healthy man in his sixties might sit at about 1.0, while another man the same age with no cancer at all can sit near 5.0. You can read more about the test itself on the NHS prostate cancer pages.

So a one-off PSA number, taken in isolation, tells you very little. What tells you something is the direction of travel: where your number sits today compared with where it sat a year or two ago. This is the same lesson that runs through almost every useful health signal in men. One reading is a snapshot. A trend is information. It is the same reason we have argued that morning wood is a poor one-off proxy for erection health: any single observation is too noisy to trust, but a pattern over time is hard to argue with.

What the UK decided in 2026

On 28 May 2026, the UK National Screening Committee confirmed the country's first ever prostate cancer screening recommendation, and it was deliberately narrow. It recommended offering a PSA test every two years, between the ages of 45 and 61, only to men who have a confirmed BRCA2 gene change and a family history of breast, ovarian, pancreatic or prostate cancer. You can read the committee's own summary on the UK NSC blog.

Just as important is what the committee decided against. It did not recommend screening the general population. It did not recommend screening Black men, who carry roughly double the lifetime risk, citing a lack of direct trial evidence. And it did not recommend screening men with a family history alone. The chair, drawing on the modelling, explained that whole-population screening might lead to a small reduction in prostate cancer deaths, but that the very high levels of overdiagnosis tipped the balance toward harm.

That reasoning deserves to be taken seriously, not dismissed. Overdiagnosis is real. If screening finds a cancer that would never have troubled you, and you are then treated for it, you can be left with incontinence or erectile dysfunction for no benefit at all. The committee is not being careless. The weaker part of the recommendation is the targeting. Screening only BRCA2 carriers sounds precise, but almost no man gets BRCA tested unless a close relative was already found to carry the gene, or unless he already has advanced cancer. The men who can be flagged for free, by ethnicity or family history, were the ones left out.

The problem with the study behind the case against screening

Much of the long-running argument that PSA screening does not save lives traces back to a large American trial called PLCO, published in 2009. It split men into a group invited for annual PSA testing and a group left to "usual care," then compared prostate cancer deaths. It found almost no difference, and that result became a cornerstone of the case against screening.

There was a deep flaw. The "usual care" group was never actually unscreened. Opportunistic PSA testing was already common in the US, so most of the control men were getting tested anyway. Surveys found that by the end of the study, over 90% of the supposed no-screening group had had at least one PSA test. A trial that compares screening to screening cannot detect the benefit of screening. The null result was, in effect, built in.

When researchers later reanalysed the same data and corrected for how much the control group had really been tested, the picture flipped: the data became consistent with screening cutting prostate cancer deaths by roughly a quarter to a third. And the cleaner European trial, ERSPC, had been positive all along. As the physician Peter Attia put it in a recent deep dive on the topic, "the timing of when you find the cancer is not a minor detail."

What happened in the US when screening was pulled back

Here is the part that turns theory into a real-world test. In 2008 and again in 2012, US advisers recommended against routine PSA screening. Screening rates fell, biopsy rates fell, and fewer early cancers were found. So far, that is what you would expect. The problem showed up a few years later.

Across both the US and Canada, diagnoses of advanced and metastatic prostate cancer, the kind that is no longer curable, began to climb. The recent figures show late-stage disease rising several percent per year, while the long decline in prostate cancer deaths stalled. This was exactly what many urologists had warned would happen when early detection was pulled back.

Screening in 2026 is not the screening the guidelines evaluated

This is the crux of the whole debate. The trials that shaped the "screening does more harm than good" verdict tested an old, crude pathway: a raised PSA led to a biopsy through the rectal wall, and any cancer found tended to be treated. That pathway produced a lot of infections, a lot of overdiagnosis, and a lot of men treated for cancers that would never have hurt them. Judging that pathway harshly is fair. The mistake is to assume nothing has changed.

The modern pathway looks very different, and it improves both sides of the ledger at once:

• PSA velocity. Instead of reading one number, doctors track the trend over years against your own baseline. A slow drift is expected with age. A sustained acceleration is the real warning sign.
• MRI before any biopsy. A prostate MRI can rule a biopsy in or out, and guide the needle when one is needed. It finds more of the dangerous cancers while sparing many men a biopsy they never needed.
• A safer biopsy route. The newer transperineal approach goes through the skin rather than the rectum, which has cut infection rates close to zero.
• Active surveillance. Low-risk cancers are now watched closely rather than treated immediately, which removes much of the overtreatment harm that drove the original worry.

The MRI step alone has strong trial backing, and it is the part that most directly answers the overdiagnosis concern.

In other words, the harms that justified the "no" are not fixed. They are properties of how screening is done, and modern screening is built to reduce them. This idea, that the trend matters more than the snapshot and that better measurement means better decisions, is the same principle behind everything we build at Adam.

The real question: if you could screen well, would you?

Strip away the politics and the population averages, and ask the question plainly. Imagine a man who can access the full modern pathway: a baseline PSA, the same test repeated so a trend can be read, a rapid MRI if anything looks off, a safe transperineal biopsy only if the MRI warrants it, and active surveillance rather than rushed treatment if a low-risk cancer turns up. Would that man choose to screen? Almost without exception, the answer is yes. The people who understand this disease best, including the urologists who treat it, overwhelmingly track their own numbers.

That answer matters, because it exposes what the population decision really is. A national "no" is an average. It is averaged across every man, every level of access, the old pathway as much as the new, and the cost to a health system of scanning millions of people. It is a reasonable answer to the question "should we run one identical programme for everyone." It is not a statement about whether early detection helps you.

For an individual with access to the modern pathway, the overdiagnosis harm is largely defused by MRI and active surveillance, while the benefit, catching an aggressive cancer while it is still curable, is preserved. His personal balance of benefit and harm is nothing like the population model's. And that, in turn, reframes the entire debate. The danger of a blanket "no" is not that screening is useless. It is that the men least able to seek out a good pathway, or who never learn to ask, are the ones left exposed. Prostate cancer follows a slow, predictable path from early and curable to late and lethal. That predictability is exactly what makes a cheap blood test, used well, so powerful.

None of this means ignoring your doctor or demanding tests without thought. It means knowing your own numbers over time, asking specifically about the modern pathway rather than a single PSA reading, and having the conversation before symptoms ever appear.